DiObex, Inc.
URL: DiObex, Inc. a clinical-stage company based in San Francisco, is developing unique, first-in-class therapies for the critically under-served metabolic disease market. Our pipeline products address the markets for the treatment of type 1 diabetes, type 2 diabetes and its co-morbidities such as hypertension, dyslipidemia and visceral adiposity (often referred to collectively as "metabolic syndrome"). Obesity is an additional therapeutic focus for the company.
| Company | DiObex, Inc. |
|---|
Data supports potential use of DIO-902 with Atorvastatin.
Development program for prevention of insulin-induced hypoglycemia in diabetes
DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases,
DiObex, Inc., a privately held biotechnology company developing treatments for metabolic diseases, announced today t...
DiObex Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases, announced today that Keith A. Vendola, MD, Head of Corporate Development, will delive...
DiObex, Inc. to Present at BIO Investor Forum 2007
DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases, announced today that CEO David Cory will deliver a corporate presentation at the upcom...
DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases,...
Top Line Data for the Treatment of Type 2 Diabetes Presented at the 67th Annual Scientific Sessions of American Diabetes Association
San Francisco, California - April 23, 2007 - DiObex, Inc., a privately held biopharmaceutical company focused on the development of therapeutics to treat metabolic disea...
SAN FRANCISCO, Calif. - March 26, 2007 - DiObex, Inc., a privately-held biopharmaceutical company focused on the development of therapeutics to treat metabolic diseases, today announced positive phase 2a results for DIO-902, a novel Cortisol S...
06/17/2008 | Taro InabaBoehringer Ingelheim announced an agreement to acquire Actimis Pharmaceuticals, Inc. one of our portfolio firms.
11/01/2007 | Nobuhiro Shimizu【Announcement of the Establishment of Beijing Office】
We are pleased to announce that Mitsui Ventures has opened a new office in Beijing in September2007.
07/18/2007 | Taro InabaMitsui Ventures Launching a New Approach to Seed Financing